Table 1.
Demographic data and clinical data of the eight patients
| Patient | Gender | Age at study onset | Disease duration | Previous treatment | EDSS at baseline | EDSS after 12 months | Relapses during first 12 months | cMRI at follow-up |
|---|---|---|---|---|---|---|---|---|
| MS1 |
Female |
41 |
0 |
None |
1.5 |
1.5 |
0 |
- |
| MS2 |
Female |
50 |
10 |
None |
1.5 |
1.5 |
1 |
New lesion |
| MS3 |
Female |
37 |
33 |
IFN-beta sc. |
1.0 |
1.5 |
0 |
stable |
| MS4 |
Female |
38 |
9 |
None |
1.0 |
1.5 |
0 |
New lesion |
| MS5 |
Female |
38 |
89 |
IFN-beta sc. |
3.5 |
2.0 |
1 |
stable |
| MS6 |
Female |
47 |
1 |
None |
1.5 |
1.5 |
0 |
New lesion |
| MS7 |
Male |
35 |
16 |
None |
1.0 |
1.0 |
0 |
New lesion |
| MS8 | Male | 25 | 55 | Mitoxantrone | 2.0 | 2.5 | 1 | New lesion |
The table shows gender, age, the previous treatment, and the EDSS scores at therapy initiation (baseline) and after 12 months. The duration from the diagnosis of definite MS to the start of GA therapy in months (disease duration) is also given. The gender ratio was 6:2 (female: male) and the average age at study onset was 38.9 ± 7.6 years (mean ± SD). Three patients had a relapse during the first 12 months after GA treatment initiation. Five patients showed a new brain lesion in the follow-up compared to pre-treatment. cMRI: cranial magnetic resonance imaging, EDSS: expanded disability status scale, sc.: subcutaneous, SD: standard deviation.